Skip to main content
Equibles

Paradigm Biocapital Advisors LP

Position in LXEO — Lexeo Therapeutics, Inc.

CIK 1855655 NEW YORK, NY
Back to LXEO Full portfolio

Position in LXEO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$19,436,403
-$16,060,526 QoQ
Shares Held
4,175,382
-32.5% QoQ
Ownership
5.09%
of shares outstanding
% of Portfolio
0.42%
of 13F equity value
Holder Rank
#8
of 141 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in LXEO Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Paradigm Biocapital Advisors LP holds $4,608,890,546 across 28 Biotechnology names. LXEO ranks #25 (0.4% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RVMD
Revolution Medicines, Inc.
 6,361,323 $1,191,348,571
2 EWTX
Edgewise Therapeutics, Inc.
 10,215,455 $415,053,936
3 GMAB
Genmab A/S
 13,133,131 $360,767,108
4 SYRE
Spyre Therapeutics, Inc.
 3,840,778 $340,984,270
5 APGE
Apogee Therapeutics, Inc.
 1,576,385 $209,233,581
6 ORKA
Oruka Therapeutics, Inc.
 2,144,526 $204,094,539
7 TNGX
Tango Therapeutics, Inc.
 6,357,523 $198,736,168
8 BLTE
Belite Bio, Inc
 1,232,877 $189,844,564

All Filings in LXEO

Export CSV
3 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $19,436,403 4,175,382
2026-03-31 $35,496,929 6,184,134
2025-12-31 $47,298,556 4,763,198